GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » EV-to-EBIT

Alembic Pharmaceuticals (BOM:533573) EV-to-EBIT : 27.96 (As of May. 18, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Alembic Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alembic Pharmaceuticals's Enterprise Value is ₹192,369 Mil. Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,880 Mil. Therefore, Alembic Pharmaceuticals's EV-to-EBIT for today is 27.96.

The historical rank and industry rank for Alembic Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

BOM:533573' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.21   Med: 17.5   Max: 39.89
Current: 27.96

During the past 13 years, the highest EV-to-EBIT of Alembic Pharmaceuticals was 39.89. The lowest was 10.21. And the median was 17.50.

BOM:533573's EV-to-EBIT is ranked worse than
69.27% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.96 vs BOM:533573: 27.96

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alembic Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹196,752 Mil. Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹6,880 Mil. Alembic Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.50%.


Alembic Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Alembic Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alembic Pharmaceuticals EV-to-EBIT Chart

Alembic Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.48 13.88 23.68 25.68 28.60

Alembic Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.68 20.58 27.13 23.90 28.60

Competitive Comparison of Alembic Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alembic Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alembic Pharmaceuticals's EV-to-EBIT falls into.



Alembic Pharmaceuticals EV-to-EBIT Calculation

Alembic Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=192368.627/6880.2
=27.96

Alembic Pharmaceuticals's current Enterprise Value is ₹192,369 Mil.
Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,880 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alembic Pharmaceuticals  (BOM:533573) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alembic Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=6880.2/196751.86305
=3.50 %

Alembic Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹196,752 Mil.
Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,880 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alembic Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alembic Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alembic Pharmaceuticals (BOM:533573) Business Description

Traded in Other Exchanges
Address
Alembic Road, Vadodara, GJ, IND, 390 003
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Alembic Pharmaceuticals (BOM:533573) Headlines

No Headlines